JP2022532356A5 - - Google Patents

Info

Publication number
JP2022532356A5
JP2022532356A5 JP2021567963A JP2021567963A JP2022532356A5 JP 2022532356 A5 JP2022532356 A5 JP 2022532356A5 JP 2021567963 A JP2021567963 A JP 2021567963A JP 2021567963 A JP2021567963 A JP 2021567963A JP 2022532356 A5 JP2022532356 A5 JP 2022532356A5
Authority
JP
Japan
Prior art keywords
drug
formulated
hour
administration
infusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021567963A
Other languages
English (en)
Japanese (ja)
Other versions
JP7801132B2 (ja
JP2022532356A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/032754 external-priority patent/WO2020232173A1/en
Publication of JP2022532356A publication Critical patent/JP2022532356A/ja
Publication of JP2022532356A5 publication Critical patent/JP2022532356A5/ja
Priority to JP2025133004A priority Critical patent/JP2025166108A/ja
Application granted granted Critical
Publication of JP7801132B2 publication Critical patent/JP7801132B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021567963A 2019-05-14 2020-05-13 抗cd38抗体を投与して多発性骨髄腫を処置する方法 Active JP7801132B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025133004A JP2025166108A (ja) 2019-05-14 2025-08-08 抗cd38抗体を投与して多発性骨髄腫を処置する方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962847825P 2019-05-14 2019-05-14
US62/847,825 2019-05-14
US201962860739P 2019-06-12 2019-06-12
US62/860,739 2019-06-12
US201962899088P 2019-09-11 2019-09-11
US62/899,088 2019-09-11
EP20305223.8 2020-03-03
EP20305223 2020-03-03
PCT/US2020/032754 WO2020232173A1 (en) 2019-05-14 2020-05-13 Methods of administering anti-cd38 antibody to treat multiple myeloma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025133004A Division JP2025166108A (ja) 2019-05-14 2025-08-08 抗cd38抗体を投与して多発性骨髄腫を処置する方法

Publications (3)

Publication Number Publication Date
JP2022532356A JP2022532356A (ja) 2022-07-14
JP2022532356A5 true JP2022532356A5 (https=) 2023-05-22
JP7801132B2 JP7801132B2 (ja) 2026-01-16

Family

ID=71094805

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021567963A Active JP7801132B2 (ja) 2019-05-14 2020-05-13 抗cd38抗体を投与して多発性骨髄腫を処置する方法
JP2025133004A Pending JP2025166108A (ja) 2019-05-14 2025-08-08 抗cd38抗体を投与して多発性骨髄腫を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025133004A Pending JP2025166108A (ja) 2019-05-14 2025-08-08 抗cd38抗体を投与して多発性骨髄腫を処置する方法

Country Status (15)

Country Link
US (1) US20210171650A1 (https=)
EP (1) EP3969004A1 (https=)
JP (2) JP7801132B2 (https=)
KR (1) KR20220008305A (https=)
CN (2) CN120501855A (https=)
AU (1) AU2020274169A1 (https=)
BR (1) BR112021022503A2 (https=)
CA (1) CA3140034A1 (https=)
CO (1) CO2021016606A2 (https=)
IL (1) IL287832A (https=)
MA (1) MA55967A (https=)
MX (1) MX2021013910A (https=)
SG (1) SG11202112513YA (https=)
TW (1) TW202108624A (https=)
WO (1) WO2020232173A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
KR20210006321A (ko) 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
KR20210030411A (ko) * 2018-07-10 2021-03-17 사노피 Cd38 및 tgf-베타를 표적으로 하는 암에 대한 병용 요법
EP3980064A1 (en) * 2019-06-10 2022-04-13 Takeda Pharmaceutical Company Limited Combination therapies using cd-38 antibodies
IL302640A (en) * 2020-11-03 2023-07-01 Sanofi Aventis Us Llc Use of isatuximab for the treatment of multiple myeloma
AU2022253256A1 (en) * 2021-04-08 2023-11-16 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and a cd38-targeted antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
JP7712206B2 (ja) * 2019-01-28 2025-07-23 サノフィ-アベンティス・ユー・エス・エルエルシー 多発性骨髄腫の処置方法

Similar Documents

Publication Publication Date Title
JP2022532356A5 (https=)
JP2023517236A5 (https=)
JP2014533279A5 (https=)
JP2020503260A5 (https=)
JP2021502961A5 (https=)
JP2019514974A5 (https=)
JP2024540054A5 (https=)
JP2021519295A5 (https=)
JP2020517696A5 (https=)
JP2022543612A5 (https=)
JP2018506550A5 (https=)
JP2003531129A5 (https=)
JP2011506483A5 (https=)
JP2017537105A5 (https=)
JP2020525411A5 (https=)
JP2022512851A5 (https=)
JP2012102122A5 (https=)
JP2015172060A5 (https=)
JP2022523372A5 (https=)
CN108778332B (zh) Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途
JP2022542472A5 (https=)
CN114224889A (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
EP3294769A1 (en) Treatment for multiple myeloma (mm)
JP2023520771A5 (https=)
JP2024511970A5 (https=)